RECURRENT NASOPHARYNGEAL CARCINOMA
Clinical trials for RECURRENT NASOPHARYNGEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT NASOPHARYNGEAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT NASOPHARYNGEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test Double-Duty immunotherapy to hold back aggressive head & neck cancer
Disease control Recruiting nowThis study is for adults whose nasopharyngeal cancer (a type of head and neck cancer linked to the Epstein-Barr virus) has returned or spread. After initial chemotherapy and immunotherapy, patients who are stable are randomly assigned to continue with standard immunotherapy alone…
Matched conditions: RECURRENT NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for Tough-to-Treat throat cancer: three drugs vs. two
Disease control Recruiting nowThis study is for people with advanced nasopharyngeal cancer (a type of throat cancer) that has spread or returned after standard treatments. It will test if adding a pill called cabozantinib to two immunotherapy drugs (nivolumab and ipilimumab) works better than the two immunoth…
Matched conditions: RECURRENT NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Advanced proton therapy tested as safer, more effective option for Tough-to-Treat recurrent head & neck cancer
Disease control Recruiting nowThis study is testing an advanced form of radiation called proton therapy for people whose nasopharyngeal cancer has returned after initial treatment. The goal is to see if this more precise radiation can better control the cancer while causing fewer severe long-term side effects…
Matched conditions: RECURRENT NASOPHARYNGEAL CARCINOMA
Phase: NA • Sponsor: Guangzhou Concord Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC